Times are tough in the healthcare industry and the rise of pharmacoeconomics — when the value of one pharmaceutical drug or drug therapy is compared to another — is not making life any easier for big pharma.
The pharmaceutical industry lies in a cloud of uncertain future policies.
Drug-resistant so-called superbugs kill at least 700,000 worldwide each year and deaths are expected to rise to 10m per year by 2050, according to economist Jim O’Neill.
Over the past few months, there has been a great deal of speculation around what kind of impact Donald Trump‘s presidency will have on healthcare and the pharmaceutical industry.
Given the scarcity of commercially-ready oncology assets, cancer drugs are appealing to big pharma with lots of cash and high prices are being paid for hopeful products.